Cleo Diagnostics Ltd (ASX:COV)

Market Cap	49.47M
Revenue (ttm)	210.81K
Net Income (ttm)	-3.10M
Shares Out	128.50M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,028
Average Volume	60,979
Open	0.4000
Previous Close	0.4000
Day's Range	0.3800 - 0.4050
52-Week Range	0.3000 - 0.6200
Beta	n/a
RSI	52.50
Earnings Date	Aug 27, 2025

About United States Steel

Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: COV